Live Analyst Rating Changes 22257 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matthew Keller
HC

Matthew Keller

H.C. Wainwright
Wall Street Analyst
★★★☆☆
#2176
on 13Foresight · ranked by our own returns
38%
Success Rate
+3.1%
Average Return
6 of 16 calls profitable · -0.4% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 38% of Matthew Keller's ratings turned a profit when each position was held for 1 year — averaging +3.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

69 Buy 3 Hold 0 Sell
Matthew's Stock Coverage 11 ratings · 2026-08-10
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
GYRE
Gyre Therapeutics
 Aug 07, 2026 BUY Strong Buy
+211.6% avg upside
15 analysts
$18.00
169.90% Upside
 +0.0% ·
IFRX
InflaRx
 Aug 06, 2026 BUY Strong Buy
+384.9% avg upside
11 analysts
$8.00
334.76% Upside
 +7.0% ·
MCRB
Seres Therapeutics
 Aug 05, 2026 BUY Buy
+242.1% avg upside
11 analysts
$12.00
146.48% Upside
 -2.7% ·
ACXP
Acurx Pharmaceuticals
 Aug 04, 2026 BUY Strong Buy
+4624.1% avg upside
4 analysts
$31.00
1913.01% Upside
 +7.7% ·
GALT
Galectin Therapeutics
 Jun 23, 2026 BUY Strong Buy
+187.4% avg upside
8 analysts
$11.00
218.85% Upside
 +10.6% ·
SXTP
60 Degrees Pharmaceuticals, Inc.
 May 20, 2026 HOLD Buy
+230.4% avg upside
2 analysts
 — -20.0% ·
GRI
GRI Bio
 May 14, 2026 BUY Strong Buy
+1204.0% avg upside
3 analysts
$10.00
580.23% Upside
 -31.6% ·
KYNB
Kyntra Bio
 May 12, 2026 BUY Buy
+339.0% avg upside
15 analysts
$43.00
491.54% Upside
 -3.4% ·
PHIO
Phio Pharmaceuticals
 May 08, 2026 BUY Strong Buy
+811.1% avg upside
3 analysts
$14.00
1246.07% Upside
 -2.8% ·
ITRMF
Iterum Therapeutics
 Mar 30, 2026 HOLD Buy
+71666566.6% avg upside
5 analysts
 — · ·
FTH
Faeth Therapeutics
 Oct 30, 2025 HOLD Strong Buy
+80.6% avg upside
16 analysts
 — +158.0% ·
🔒 6 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Matthew Keller — Frequently Asked Questions
How accurate are Matthew Keller's stock ratings?
Based on the calls 13Foresight could measure, about 38% of Matthew's ratings were profitable over a one-year hold, with an average return of +3.1% per rating, or -0.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Matthew ranked on 13Foresight?
Matthew Keller is currently ranked #2176 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matthew cover?
Matthew most recently has ratings on GYRE, IFRX, MCRB, ACXP, GALT, SXTP, GRI, KYNB, PHIO, ITRMF, FTH. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.